Interestingly, when HDAC6 inhibitor (ACY1215) was combined with meticrane, a significantly high impact on the viability of tumor cells (K562, Jurkat and SK-hep-1) were observed (Supplementary Figures 4A-C). This evidence concerns the gene HDAC6 and neoplasm.